Revolution Medicines (RVMD) Cash & Equivalents (2019 - 2026)
Revolution Medicines (RVMD) posted quarterly Cash & Equivalents of $440.9 million for Q1 2026, up 32.19% year-over-year from $333.6 million in Q1 2025, and up 14.9% quarter-over-quarter from $383.7 million in Q4 2025.
Revolution Medicines (RVMD) Cash & Equivalents (2019 - 2026) Analysis & Trends
Revolution Medicines' Cash & Equivalents history runs 8 years deep, the most recent figure standing at $440.9 million for Q1 2026.
- In Q1 2026, Cash & Equivalents rose 32.19% year-over-year to $440.9 million; the TTM figure through Mar 2026 stood at $440.9 million (up 32.19% YoY), while the FY2025 annual figure was $383.7 million, down 29.34% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $440.9 million, up from $383.7 million in the prior quarter.
- The five-year high for Cash & Equivalents was $696.1 million in Q4 2023, with the low at $97.7 million in Q1 2022.
- The 5-year median for Cash & Equivalents is $333.6 million (2025), against an average of $323.1 million.
- The sharpest annual moves came in 2022 and 2023: Cash & Equivalents tumbled 72.22% in 2022, then surged 337.43% in 2023.
- Revolution Medicines' Cash & Equivalents stood at $161.4 million in 2022, then surged by 331.29% to $696.1 million in 2023, then fell by 21.99% to $543.1 million in 2024, then slipped by 29.34% to $383.7 million in 2025, then advanced by 14.9% to $440.9 million in 2026.
- Business Quant data shows RVMD's Cash & Equivalents at $440.9 million in Q1 2026, $383.7 million in Q4 2025, and $217.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 1.25 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 815.44 Mn |
| Mar 31, 2026 | 440.94 Mn |
| Dec 31, 2025 | 383.75 Mn |
| Sep 30, 2025 | 217.44 Mn |
| Jun 30, 2025 | 402.44 Mn |
| Mar 31, 2025 | 333.55 Mn |
| Dec 31, 2024 | 543.06 Mn |
| Sep 30, 2024 | 201.26 Mn |
| Jun 30, 2024 | 275.71 Mn |
| Mar 31, 2024 | 288.43 Mn |
| Dec 31, 2023 | 696.15 Mn |
| Sep 30, 2023 | 358.40 Mn |
| Jun 30, 2023 | 380.33 Mn |
| Mar 31, 2023 | 427.22 Mn |
| Dec 31, 2022 | 161.41 Mn |
| Sep 30, 2022 | 178.94 Mn |
| Jun 30, 2022 | 105.78 Mn |
| Mar 31, 2022 | 97.67 Mn |
| Dec 31, 2021 | 108.50 Mn |
| Sep 30, 2021 | 129.15 Mn |